Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
§ Phase of development
§ Approved
§ Pre-registration & Phase III
§ Phase II & Phase II/III
§ Type of molecule
§ Cell and gene therapies
§ Monoclonal antibodies
§ Proteins
§ Peptides (recombinant)
§ Vaccines
§ Others
§ Target therapeutic area
§ Autoimmune disorders
§ Blood disorders
§ Bone disorders
§ Genetic disorders
§ Metabolic disorders
§ Neurological disorders
§ Oncological disorders
§ Respiratory disorders
§ Others
§ Type of drug delivery system
§ Large volume wearable injectors
§ Autoinjectors
§ Prefilled syringes
§ Needle-free injectors
§ Drug reconstitution systems
To Request for sample - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
§ Revenues from licensing deals
§ Upfront payments
§ Milestone payments
§ Key geographical regions
§ North America
§ Europe
§ Asia Pacific
§ Rest of the World
The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030”report features the following companies, which we identified to be key players in this domain:
§ Adocia
§ Ajinomoto Bio-Pharma Services
§ Arecor
§ Alteogen
§ Ascendis Pharma
§ Avadel Pharmaceuticals
§ Camurus
§ Creative BioMart
§ Creative Biolabs
§ DURECT
§ Eagle Pharmaceuticals
§ Halozyme Therapeutics
§ MedinCell
§ Xeris Pharmaceuticals
§ Serina Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Subcutaneous Biologics: Current Market Landscape
5. Case Study: Leading Subcutaneous Biologics
6. Subcutaneous Formulation Technologies: Current Market Landscape
7. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis
8. Subcutaneous Formulation Technology Developers: Company Profiles
9. Partnerships and Collaborations
10. Subcutaneous Drug Delivery Systems: Current Market Landscape
11. Swot Analysis
12. Market Forecast and Opportunity Analysis
13. Concluding Remarks
14. Executive Insights
15. Appendix 1: Tabulated Data
16. Appendix 2: List Of Companies And Organization
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
1. Global Autoinjectors Market (3rd Edition), 2020-2030
2. Prefilled Syringes Market (5th Edition), 2020-2030
3. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030
4.
